Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TRANDATE HCT vs ALDORIL D50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.
Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.
Treatment of hypertension,Management of hypertensive urgency (off-label)
Hypertension (first-line or second-line therapy),Hypertensive urgency (off-label)
Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.
1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.
Labetalol: terminal elimination half-life is 6-8 hours (range 3-16 hours) consistent with twice-daily dosing. Hydrochlorothiazide: terminal half-life 9-10 hours (range 6-15 hours), prolonged in renal impairment.
3–6 hours (terminal elimination half-life); clinical context: requires twice-daily dosing for sustained blood pressure control; prolonged in renal impairment.
Labetalol is extensively metabolized primarily via glucuronidation (direct conjugation) and minor CYP2D6-mediated oxidation to an inactive metabolite. Hydrochlorothiazide is not metabolized; it is excreted unchanged in urine.
Methyldopa is extensively metabolized in the liver via conjugation and O-methylation, with involvement of catechol-O-methyltransferase (COMT). Hydrochlorothiazide is not extensively metabolized; it is eliminated largely unchanged by the kidneys.
Labetalol is primarily excreted in urine as unchanged drug (approximately 55-60%) and as glucuronide conjugates. About 12-27% is excreted in feces via biliary elimination. Hydrochlorothiazide is excreted unchanged in urine (≥95%) via renal tubular secretion. Total renal elimination of labetalol: ~55-60% unchanged; HCTZ: ~95% unchanged.
Renal: 50% as unchanged drug and 20% as metabolites; biliary/fecal: ~25% (as metabolites); total renal clearance accounts for ~70% of elimination.
Labetalol: ~50% bound to albumin. Hydrochlorothiazide: ~40-68% bound to albumin and alpha-1-acid glycoprotein.
~20% bound to albumin; minimal binding to other plasma proteins.
Labetalol: Vd 3-16 L/kg (mean 11 L/kg), indicating extensive tissue distribution. Hydrochlorothiazide: Vd 0.8-1.5 L/kg (mean 1 L/kg), limited distribution.
0.2–0.3 L/kg (moderately low Vd, indicating limited extravascular distribution and predominantly plasma water distribution).
Labetalol: oral bioavailability is 25-40% due to extensive first-pass metabolism. Hydrochlorothiazide: oral bioavailability is 65-75% (fasted).
Oral: 30–40% (due to extensive first-pass metabolism); IV: 100%.
GFR 30-90 m L/min: No adjustment. GFR <30 m L/min: Contraindicated due to hydrochlorothiazide component.
Contraindicated if GFR < 30 m L/min; for GFR 30-50 m L/min: reduce dose and monitor electrolytes.
Child-Pugh A: Use with caution; reduce labetalol dose. Child-Pugh B or C: Contraindicated due to extensive hepatic metabolism of labetalol.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: contraindicated.
Not recommended; safety and efficacy not established for labetalol/hydrochlorothiazide combination.
Not recommended; inadequate safety data.
Start at lowest dose (100/25 mg daily); titrate slowly due to increased risk of hypotension and electrolyte imbalance.
Start with 1 tablet (hydrochlorothiazide 12.5 mg + methyldopa 125 mg) once daily; increase slowly; monitor for hypotension and electrolyte imbalance.
None
None
Beta-blocker withdrawal: abrupt discontinuation may exacerbate angina or precipitate myocardial infarction in patients with coronary artery disease. Bronchospasm: avoid in patients with bronchial asthma or COPD. Heart failure: caution in patients with decompensated heart failure; may precipitate worsening. Peripheral vascular disease: may worsen symptoms. Hepatic impairment: labetalol is hepatically metabolized; use caution. Renal impairment: hydrochlorothiazide may be ineffective with Cr Cl <30 m L/min. Electrolyte disturbances: monitor potassium, sodium, magnesium; risk of hypokalemia, hyponatremia, hypomagnesemia. Hyperuricemia: can precipitate gout. Photosensitivity: with hydrochlorothiazide. Exacerbation of systemic lupus erythematosus: reported with thiazides. DM: beta-blockers may mask hypoglycemia. Surgery: withdrawal before elective surgery recommended.
Sedation and drowsiness common; avoid driving or hazardous activities. Risk of Coombs-positive hemolytic anemia with methyldopa (discontinue if anemia develops). Hepatotoxicity and liver function abnormalities (discontinue if jaundice occurs). Orthostatic hypotension; caution in volume-depleted patients. Electrolyte imbalances (particularly hypokalemia, hyponatremia) with hydrochlorothiazide; monitor serum electrolytes. Sulfonamide cross-sensitivity possible. Exacerbation of systemic lupus erythematosus. Avoid abrupt withdrawal of methyldopa (may cause rebound hypertension).
Absolute: sinus bradycardia, heart block greater than first degree, cardiogenic shock, decompensated heart failure, bronchial asthma, hypersensitivity to labetalol, hydrochlorothiazide, or sulfonamide-derived drugs, anuria. Relative: diabetes mellitus, hyperthyroidism, pheochromocytoma (labetalol may paradoxically elevate blood pressure), severe renal impairment (Cr Cl <30 m L/min for thiazide efficacy).
Active hepatic disease (cirrhosis, hepatitis) associated with methyldopa therapy; previous methyldopa-induced liver disorders. Anuria or hypersensitivity to thiazide diuretics or sulfonamide-derived drugs. Concomitant use with MAO inhibitors. Severe renal impairment (creatinine clearance <30 m L/min) or electrolyte depletion due to hydrochlorothiazide. Concurrent lithium therapy (risk of lithium toxicity).
Avoid tyramine-rich foods (aged cheese, cured meats, fermented soy products) due to potential hypertensive crises. Limit caffeine intake; may increase heart rate. Avoid excessive potassium-rich foods or supplements unless monitored due to hydrochlorothiazide's potassium-wasting effect. Take with food to reduce GI upset.
Avoid potassium supplements or salt substitutes containing potassium without consulting doctor. Limit alcohol intake. Avoid excessive grapefruit juice. Maintain adequate potassium intake through diet to prevent hypokalemia.
First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, hypoglycemia, and respiratory depression; intrauterine growth restriction reported with chronic use.
Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester may cause fetal/neonatal effects including electrolyte disturbances, jaundice, thrombocytopenia, and possible fetal growth restriction. Methyldopa has not shown teratogenicity. Aldoril D50 (M 500mg/HCTZ 50mg) is not recommended during pregnancy, especially after first trimester.
Labetalol is excreted into breast milk in low amounts (M/P ratio ~0.6-0.8); generally considered compatible with breastfeeding; monitor infant for bradycardia and hypotension.
Both methyldopa and HCTZ are excreted in breast milk. Methyldopa M/P ratio approximately 1.0; HCTZ M/P ratio variable, small amounts. Use during breastfeeding may suppress lactation due to HCTZ diuretic effect. Monitor infant for signs of hypotension, electrolyte imbalance. Caution recommended; use only if clearly needed.
No standard dose adjustment required; however, pregnancy may alter labetalol pharmacokinetics (increased clearance, decreased half-life) potentially necessitating dose titration based on clinical response.
Pregnancy-induced increase in plasma volume may reduce effectiveness of HCTZ, requiring dose adjustment. Methyldopa pharmacokinetics not significantly altered; however, increased clearance in pregnancy may require higher doses. In preeclampsia, dose adjustments may be needed. Avoid HCTZ in pregnancy if possible.
Trandate HCT combines labetalol (alpha/beta blocker) and hydrochlorothiazide. Monitor heart rate, blood pressure, and electrolytes. Avoid in asthma, COPD, bradycardia, heart block, and anuria. Taper if discontinuing. May mask hypoglycemia in diabetics. Can cause orthostatic hypotension; dose at bedtime initially.
ALDORIL D50 combines methyldopa and hydrochlorothiazide. Monitor for orthostatic hypotension, especially in volume-depleted patients. May cause positive Coombs test, hemolytic anemia, and lupus-like syndrome. Avoid in pheochromocytoma. Use caution in hepatic disease.
Take exactly as prescribed, usually once daily, with or without food.,Do not stop suddenly; tapering is necessary to avoid rebound hypertension.,May cause dizziness or lightheadedness; rise slowly from sitting or lying.,Avoid alcohol; it can worsen dizziness and side effects.,Inform your doctor if you experience slow heartbeat, fainting, swelling of feet/ankles, or unusual weight gain.,May cause photosensitivity; use sunscreen and protective clothing.,Monitor blood pressure regularly at home.
Take exactly as prescribed; do not skip doses or double up.,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Report unexplained fever, jaundice, or dark urine immediately.,Avoid sudden discontinuation; may cause rapid increase in blood pressure.,Stay hydrated but do not overhydrate; monitor for signs of electrolyte imbalance.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TRANDATE HCT vs ALDORIL D50, answered by our medical review team.
TRANDATE HCT is a Antihypertensive Combination that works by TRANDATE HCT is a combination of labetalol, a non-selective beta-blocker with selective alpha-1 blocking activity, and hydrochlorothiazide, a thiazide diuretic. Labetalol reduces peripheral vascular resistance via alpha-1 blockade and decreases heart rate and cardiac output via beta-blockade. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, promoting diuresis and reducing plasma volume.. ALDORIL D50 is a Antihypertensive Combination that works by Aldoril D50 is a combination of methyldopa and hydrochlorothiazide. Methyldopa is a centrally-acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume and further lowering blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TRANDATE HCT and ALDORIL D50 depend on the specific clinical indication. These are both Antihypertensive Combination agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TRANDATE HCT is: Oral: 100 mg labetalol/25 mg hydrochlorothiazide twice daily, titrated based on blood pressure response; maximum 1200 mg labetalol/300 mg hydrochlorothiazide daily.. The standard adult dose of ALDORIL D50 is: 1 tablet (hydrochlorothiazide 25 mg + methyldopa 250 mg) orally twice daily; maximum dose: 2 tablets (50 mg + 500 mg) twice daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TRANDATE HCT and ALDORIL D50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TRANDATE HCT is classified as Category C. First trimester: No clear association with major malformations in limited human data; labetalol crosses placenta. Second/third trimester: Potential fetal bradycardia, hypotension, . ALDORIL D50 is classified as Category C. Hydrochlorothiazide (HCTZ) is Pregnancy Category B in first trimester and Category D in second/third trimesters. Methyldopa (M) is Category B. HCTZ use in second/third trimester ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.